Recent advances in diagnosis, treatment, and prognosis of IgG4-related autoimmune pancreatitis: a narrative review

被引：1

作者：

He, Xin ^{[1
]}

Sun, Boyuan ^{[1
]}

Nie, Yuxue ^{[2
]}

Zhang, Wen ^{[2
,3
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Rheumatol,MD Program, Beijing, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Dermatol & Immunol Dis, State Key Lab Complex Severe & Rare Dis, Dept Rheumatol,Peking Union Med Coll Hosp, Beijing, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Rheumatol, 1 Shuaifuyuan, Beijing 100730, Peoples R China

来源：

JOURNAL OF PANCREATOLOGY | 2022年 / 5卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Autoimmune pancreatitis; IgG4-related disease; Immunoglobulin G4; IMMUNOGLOBULIN G4-RELATED DISEASE; SCLEROSING CHOLANGITIS; F-18-FDG PET/CT; MALIGNANCY; EFFICACY; CRITERIA; RELAPSE; INVOLVEMENT; INCREASES; RITUXIMAB;

D O I：

10.1097/JP9.0000000000000112

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Immunoglobulin G4 (IgG4)-related autoimmune pancreatitis (AIP), also known as "type 1 AIP," is a rare, chronic, and fibroinflammatory disease manifested as obstructive jaundice and enlargement of the pancreas, usually accompanied by extra-pancreatic organ involvement. The understanding of IgG4-related AIP is gradually deepening. In this review, we summarized the basic concepts, common clinical manifestations, and new progress of the disease including diagnostic, therapeutic strategies, and prognosis mainly based on published case reports, cohort studies, meta-analyses, and guidelines in the past 5 years. Issues such as diagnostic markers, risk factors for relapse, and more effective treatment still need to be further studied.

引用

页码：202 / 209

页数：8